Literature DB >> 29910642

Progress in breast cancer-can we do better?

S F Dent1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29910642      PMCID： PMC6001766          DOI： 10.3747/co.25.4159

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  7 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Authors:  David Cameron; Martine J Piccart-Gebhart; Richard D Gelber; Marion Procter; Aron Goldhirsch; Evandro de Azambuja; Gilberto Castro; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Nedal Al-Sakaff; Sabine Lauer; Eleanor McFadden; Brian Leyland-Jones; Richard Bell; Mitch Dowsett; Christian Jackisch
Journal:  Lancet       Date:  2017-02-17       Impact factor: 79.321

3.  The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.

Authors:  Stephen K Chia; Caroline H Speers; Yulia D'yachkova; Anna Kang; Suzanne Malfair-Taylor; Jeff Barnett; Andy Coldman; Karen A Gelmon; Susan E O'reilly; Ivo A Olivotto
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

4.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Authors:  Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

Review 5.  Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.

Authors:  Amelie Schramm; Nikolaus De Gregorio; Peter Widschwendter; Visnja Fink; Jens Huober
Journal:  Breast Care (Basel)       Date:  2015-06-18       Impact factor: 2.860

Review 6.  HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.

Authors:  Sarah L Sammons; Donna L Topping; Kimberly L Blackwell
Journal:  Curr Cancer Drug Targets       Date:  2017       Impact factor: 3.428

Review 7.  Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.

Authors: 
Journal:  Lancet Oncol       Date:  2017-12-11       Impact factor: 41.316
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.